nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—pancreatic cancer—kidney cancer	0.195	0.553	CtDrD
Erlotinib—lung cancer—kidney cancer	0.157	0.447	CtDrD
Erlotinib—CYP1A1—kidney cancer	0.0677	0.653	CbGaD
Erlotinib—PIP4K2C—Pazopanib—kidney cancer	0.0379	0.0989	CbGbCtD
Erlotinib—ABCB1—kidney cancer	0.036	0.347	CbGaD
Erlotinib—AURKC—Pazopanib—kidney cancer	0.0301	0.0786	CbGbCtD
Erlotinib—TNK1—Sunitinib—kidney cancer	0.0178	0.0465	CbGbCtD
Erlotinib—ULK3—Sunitinib—kidney cancer	0.0178	0.0465	CbGbCtD
Erlotinib—AURKC—Sorafenib—kidney cancer	0.0175	0.0456	CbGbCtD
Erlotinib—MKNK1—Sorafenib—kidney cancer	0.0175	0.0456	CbGbCtD
Erlotinib—STK10—Pazopanib—kidney cancer	0.0173	0.0451	CbGbCtD
Erlotinib—MAP2K5—Pazopanib—kidney cancer	0.0157	0.0411	CbGbCtD
Erlotinib—MAP3K19—Pazopanib—kidney cancer	0.0145	0.0377	CbGbCtD
Erlotinib—AURKC—Sunitinib—kidney cancer	0.0141	0.0369	CbGbCtD
Erlotinib—FLT3—Sorafenib—kidney cancer	0.0126	0.033	CbGbCtD
Erlotinib—SLK—Sunitinib—kidney cancer	0.0118	0.0309	CbGbCtD
Erlotinib—EPHA6—Sorafenib—kidney cancer	0.0112	0.0291	CbGbCtD
Erlotinib—HIPK4—Sorafenib—kidney cancer	0.0112	0.0291	CbGbCtD
Erlotinib—NR1I2—Paclitaxel—kidney cancer	0.0103	0.0268	CbGbCtD
Erlotinib—FLT3—Sunitinib—kidney cancer	0.0102	0.0267	CbGbCtD
Erlotinib—STK10—Sorafenib—kidney cancer	0.01	0.0262	CbGbCtD
Erlotinib—MAP2K5—Sorafenib—kidney cancer	0.00913	0.0238	CbGbCtD
Erlotinib—HIPK4—Sunitinib—kidney cancer	0.00904	0.0236	CbGbCtD
Erlotinib—MAP3K19—Sorafenib—kidney cancer	0.00839	0.0219	CbGbCtD
Erlotinib—STK10—Sunitinib—kidney cancer	0.00812	0.0212	CbGbCtD
Erlotinib—MAP2K5—Sunitinib—kidney cancer	0.00739	0.0193	CbGbCtD
Erlotinib—STK10—renal vein—kidney cancer	0.00728	0.246	CbGeAlD
Erlotinib—MAP3K19—Sunitinib—kidney cancer	0.0068	0.0177	CbGbCtD
Erlotinib—UGT1A1—Pazopanib—kidney cancer	0.00519	0.0135	CbGbCtD
Erlotinib—STK10—renal artery—kidney cancer	0.0049	0.165	CbGeAlD
Erlotinib—CYP1B1—Paclitaxel—kidney cancer	0.00392	0.0102	CbGbCtD
Erlotinib—UGT1A1—Sorafenib—kidney cancer	0.00301	0.00786	CbGbCtD
Erlotinib—CYP3A5—Temsirolimus—kidney cancer	0.00301	0.00786	CbGbCtD
Erlotinib—ABCG2—Pazopanib—kidney cancer	0.00285	0.00745	CbGbCtD
Erlotinib—ABCG2—Dactinomycin—kidney cancer	0.00261	0.00681	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—kidney cancer	0.00211	0.00552	CbGbCtD
Erlotinib—ABCB1—Temsirolimus—kidney cancer	0.00196	0.00511	CbGbCtD
Erlotinib—ABCG2—Paclitaxel—kidney cancer	0.00186	0.00487	CbGbCtD
Erlotinib—CYP2D6—Temsirolimus—kidney cancer	0.00185	0.00482	CbGbCtD
Erlotinib—CYP3A4—Everolimus—kidney cancer	0.00174	0.00454	CbGbCtD
Erlotinib—ABCG2—Sorafenib—kidney cancer	0.00166	0.00432	CbGbCtD
Erlotinib—ABCG2—Vincristine—kidney cancer	0.00161	0.0042	CbGbCtD
Erlotinib—CYP2C8—Pazopanib—kidney cancer	0.00152	0.00397	CbGbCtD
Erlotinib—ABCG2—Sunitinib—kidney cancer	0.00134	0.0035	CbGbCtD
Erlotinib—UGT1A1—urine—kidney cancer	0.0013	0.0438	CbGeAlD
Erlotinib—CYP1A2—Pazopanib—kidney cancer	0.00118	0.00307	CbGbCtD
Erlotinib—CYP3A4—Temsirolimus—kidney cancer	0.00117	0.00306	CbGbCtD
Erlotinib—CYP3A5—Paclitaxel—kidney cancer	0.00103	0.0027	CbGbCtD
Erlotinib—ABCB1—Pazopanib—kidney cancer	0.00103	0.00269	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—kidney cancer	0.001	0.00262	CbGbCtD
Erlotinib—CYP2C8—Paclitaxel—kidney cancer	0.000993	0.00259	CbGbCtD
Erlotinib—CYP2D6—Pazopanib—kidney cancer	0.00097	0.00253	CbGbCtD
Erlotinib—ABCB1—Dactinomycin—kidney cancer	0.000941	0.00246	CbGbCtD
Erlotinib—CYP3A5—Sorafenib—kidney cancer	0.000917	0.00239	CbGbCtD
Erlotinib—CYP3A5—Vincristine—kidney cancer	0.000891	0.00232	CbGbCtD
Erlotinib—CYP2C8—Sorafenib—kidney cancer	0.000882	0.0023	CbGbCtD
Erlotinib—ABCB1—Gemcitabine—kidney cancer	0.000744	0.00194	CbGbCtD
Erlotinib—CYP3A5—Sunitinib—kidney cancer	0.000743	0.00194	CbGbCtD
Erlotinib—HIPK4—gonad—kidney cancer	0.000723	0.0244	CbGeAlD
Erlotinib—CYP1A2—Sorafenib—kidney cancer	0.000683	0.00178	CbGbCtD
Erlotinib—ABCB1—Paclitaxel—kidney cancer	0.000672	0.00175	CbGbCtD
Erlotinib—AURKC—gonad—kidney cancer	0.000617	0.0208	CbGeAlD
Erlotinib—CYP3A4—Pazopanib—kidney cancer	0.000617	0.00161	CbGbCtD
Erlotinib—ABCB1—Sorafenib—kidney cancer	0.000597	0.00156	CbGbCtD
Erlotinib—ABCB1—Vinblastine—kidney cancer	0.00059	0.00154	CbGbCtD
Erlotinib—ABCB1—Vincristine—kidney cancer	0.00058	0.00151	CbGbCtD
Erlotinib—CYP1A2—urine—kidney cancer	0.000574	0.0194	CbGeAlD
Erlotinib—EPHA6—gonad—kidney cancer	0.000571	0.0193	CbGeAlD
Erlotinib—CYP2D6—Sorafenib—kidney cancer	0.000563	0.00147	CbGbCtD
Erlotinib—CYP2D6—Vinblastine—kidney cancer	0.000556	0.00145	CbGbCtD
Erlotinib—PIP4K2C—nephron tubule—kidney cancer	0.000499	0.0169	CbGeAlD
Erlotinib—ABCB1—Sunitinib—kidney cancer	0.000484	0.00126	CbGbCtD
Erlotinib—Vandetanib—KDR—kidney cancer	0.000463	0.409	CrCbGaD
Erlotinib—FLT3—gonad—kidney cancer	0.000451	0.0152	CbGeAlD
Erlotinib—PIP4K2C—cortex of kidney—kidney cancer	0.000427	0.0144	CbGeAlD
Erlotinib—SLK—nephron tubule—kidney cancer	0.000425	0.0144	CbGeAlD
Erlotinib—CYP3A4—urine—kidney cancer	0.000416	0.014	CbGeAlD
Erlotinib—CYP2D6—urine—kidney cancer	0.000409	0.0138	CbGeAlD
Erlotinib—ULK3—cortex of kidney—kidney cancer	0.000408	0.0138	CbGeAlD
Erlotinib—PIP4K2C—gonad—kidney cancer	0.000407	0.0138	CbGeAlD
Erlotinib—PIP4K2C—cardiac atrium—kidney cancer	0.000407	0.0137	CbGeAlD
Erlotinib—CYP3A4—Paclitaxel—kidney cancer	0.000403	0.00105	CbGbCtD
Erlotinib—Vandetanib—VEGFA—kidney cancer	0.000392	0.347	CrCbGaD
Erlotinib—ULK3—gonad—kidney cancer	0.000389	0.0131	CbGeAlD
Erlotinib—ULK3—cardiac atrium—kidney cancer	0.000388	0.0131	CbGeAlD
Erlotinib—MKNK1—cortex of kidney—kidney cancer	0.000384	0.013	CbGeAlD
Erlotinib—MKNK1—gonad—kidney cancer	0.000366	0.0124	CbGeAlD
Erlotinib—MKNK1—cardiac atrium—kidney cancer	0.000365	0.0123	CbGeAlD
Erlotinib—SLK—cortex of kidney—kidney cancer	0.000364	0.0123	CbGeAlD
Erlotinib—ABCB1—Doxorubicin—kidney cancer	0.000362	0.000946	CbGbCtD
Erlotinib—CYP3A4—Sorafenib—kidney cancer	0.000358	0.000934	CbGbCtD
Erlotinib—CYP3A4—Vinblastine—kidney cancer	0.000353	0.000922	CbGbCtD
Erlotinib—CYP3A4—Vincristine—kidney cancer	0.000347	0.000907	CbGbCtD
Erlotinib—SLK—cardiac atrium—kidney cancer	0.000346	0.0117	CbGeAlD
Erlotinib—CYP2D6—Doxorubicin—kidney cancer	0.000341	0.000891	CbGbCtD
Erlotinib—STK10—renal system—kidney cancer	0.000336	0.0114	CbGeAlD
Erlotinib—STK10—kidney—kidney cancer	0.000325	0.011	CbGeAlD
Erlotinib—UGT1A1—renal system—kidney cancer	0.000317	0.0107	CbGeAlD
Erlotinib—UGT1A1—kidney—kidney cancer	0.000307	0.0104	CbGeAlD
Erlotinib—STK10—gonad—kidney cancer	0.000301	0.0102	CbGeAlD
Erlotinib—CYP3A4—Sunitinib—kidney cancer	0.00029	0.000757	CbGbCtD
Erlotinib—MAP2K5—cortex of kidney—kidney cancer	0.000282	0.00954	CbGeAlD
Erlotinib—MAP2K5—cardiac atrium—kidney cancer	0.000269	0.00908	CbGeAlD
Erlotinib—ABL1—nephron tubule—kidney cancer	0.000255	0.0086	CbGeAlD
Erlotinib—ABL1—Epirubicin—Doxorubicin—kidney cancer	0.000243	0.333	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—kidney cancer	0.000243	0.333	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—kidney cancer	0.000243	0.333	CbGdCrCtD
Erlotinib—SLCO2B1—renal system—kidney cancer	0.000233	0.00789	CbGeAlD
Erlotinib—ABL1—renal system—kidney cancer	0.000231	0.00782	CbGeAlD
Erlotinib—SLCO2B1—kidney—kidney cancer	0.000226	0.00763	CbGeAlD
Erlotinib—ABL1—kidney—kidney cancer	0.000224	0.00756	CbGeAlD
Erlotinib—ABL1—cortex of kidney—kidney cancer	0.000218	0.00736	CbGeAlD
Erlotinib—CYP3A4—Doxorubicin—kidney cancer	0.000217	0.000567	CbGbCtD
Erlotinib—CYP1B1—nephron tubule—kidney cancer	0.000216	0.00729	CbGeAlD
Erlotinib—ABL1—gonad—kidney cancer	0.000208	0.00701	CbGeAlD
Erlotinib—ABL1—cardiac atrium—kidney cancer	0.000207	0.007	CbGeAlD
Erlotinib—CYP1B1—renal system—kidney cancer	0.000196	0.00662	CbGeAlD
Erlotinib—CYP1B1—kidney—kidney cancer	0.000189	0.0064	CbGeAlD
Erlotinib—CYP1B1—cortex of kidney—kidney cancer	0.000185	0.00624	CbGeAlD
Erlotinib—Gefitinib—CYP1A1—kidney cancer	0.00018	0.159	CrCbGaD
Erlotinib—CYP1B1—gonad—kidney cancer	0.000176	0.00594	CbGeAlD
Erlotinib—ABCG2—nephron tubule—kidney cancer	0.000161	0.00543	CbGeAlD
Erlotinib—CYP2C8—renal system—kidney cancer	0.00015	0.00507	CbGeAlD
Erlotinib—CYP3A5—nephron tubule—kidney cancer	0.000149	0.00504	CbGeAlD
Erlotinib—CYP2C8—kidney—kidney cancer	0.000145	0.0049	CbGeAlD
Erlotinib—CYP1A2—renal system—kidney cancer	0.00014	0.00475	CbGeAlD
Erlotinib—CYP1A1—renal system—kidney cancer	0.000139	0.00468	CbGeAlD
Erlotinib—CYP3A5—renal system—kidney cancer	0.000135	0.00458	CbGeAlD
Erlotinib—CYP1A1—kidney—kidney cancer	0.000134	0.00453	CbGeAlD
Erlotinib—CYP3A5—kidney—kidney cancer	0.000131	0.00443	CbGeAlD
Erlotinib—CYP3A5—cortex of kidney—kidney cancer	0.000128	0.00431	CbGeAlD
Erlotinib—CYP1A1—cardiac atrium—kidney cancer	0.000124	0.00419	CbGeAlD
Erlotinib—CYP3A4—renal system—kidney cancer	0.000102	0.00344	CbGeAlD
Erlotinib—CYP2D6—renal system—kidney cancer	0.0001	0.00338	CbGeAlD
Erlotinib—CYP3A4—kidney—kidney cancer	9.83e-05	0.00332	CbGeAlD
Erlotinib—CYP2D6—kidney—kidney cancer	9.67e-05	0.00327	CbGeAlD
Erlotinib—Gefitinib—ABCB1—kidney cancer	9.56e-05	0.0846	CrCbGaD
Erlotinib—ABCB1—nephron tubule—kidney cancer	7.92e-05	0.00268	CbGeAlD
Erlotinib—ABCB1—renal system—kidney cancer	7.2e-05	0.00243	CbGeAlD
Erlotinib—ABCB1—kidney—kidney cancer	6.96e-05	0.00235	CbGeAlD
Erlotinib—ABCB1—cortex of kidney—kidney cancer	6.78e-05	0.00229	CbGeAlD
Erlotinib—ABCB1—gonad—kidney cancer	6.45e-05	0.00218	CbGeAlD
Erlotinib—Pain—Dactinomycin—kidney cancer	3.65e-05	0.000455	CcSEcCtD
Erlotinib—Anorexia—Vincristine—kidney cancer	3.64e-05	0.000453	CcSEcCtD
Erlotinib—Hepatic failure—Doxorubicin—kidney cancer	3.63e-05	0.000452	CcSEcCtD
Erlotinib—Oedema—Gemcitabine—kidney cancer	3.62e-05	0.000451	CcSEcCtD
Erlotinib—Infection—Gemcitabine—kidney cancer	3.59e-05	0.000448	CcSEcCtD
Erlotinib—Back pain—Paclitaxel—kidney cancer	3.59e-05	0.000447	CcSEcCtD
Erlotinib—Dizziness—Vinblastine—kidney cancer	3.58e-05	0.000446	CcSEcCtD
Erlotinib—Dizziness—Everolimus—kidney cancer	3.57e-05	0.000445	CcSEcCtD
Erlotinib—Body temperature increased—Sunitinib—kidney cancer	3.56e-05	0.000444	CcSEcCtD
Erlotinib—Abdominal pain—Sunitinib—kidney cancer	3.56e-05	0.000444	CcSEcCtD
Erlotinib—Nervous system disorder—Gemcitabine—kidney cancer	3.55e-05	0.000442	CcSEcCtD
Erlotinib—Thrombocytopenia—Gemcitabine—kidney cancer	3.54e-05	0.000441	CcSEcCtD
Erlotinib—Renal failure acute—Doxorubicin—kidney cancer	3.53e-05	0.00044	CcSEcCtD
Erlotinib—Haemoglobin—Capecitabine—kidney cancer	3.52e-05	0.000438	CcSEcCtD
Erlotinib—Skin disorder—Gemcitabine—kidney cancer	3.51e-05	0.000438	CcSEcCtD
Erlotinib—Hepatitis—Capecitabine—kidney cancer	3.5e-05	0.000436	CcSEcCtD
Erlotinib—Haemorrhage—Capecitabine—kidney cancer	3.5e-05	0.000436	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dactinomycin—kidney cancer	3.49e-05	0.000435	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Vincristine—kidney cancer	3.47e-05	0.000433	CcSEcCtD
Erlotinib—Urinary tract disorder—Capecitabine—kidney cancer	3.46e-05	0.000431	CcSEcCtD
Erlotinib—Insomnia—Vincristine—kidney cancer	3.45e-05	0.00043	CcSEcCtD
Erlotinib—Anorexia—Gemcitabine—kidney cancer	3.45e-05	0.00043	CcSEcCtD
Erlotinib—Vomiting—Vinblastine—kidney cancer	3.45e-05	0.000429	CcSEcCtD
Erlotinib—Connective tissue disorder—Capecitabine—kidney cancer	3.44e-05	0.000428	CcSEcCtD
Erlotinib—Vomiting—Everolimus—kidney cancer	3.43e-05	0.000428	CcSEcCtD
Erlotinib—Urethral disorder—Capecitabine—kidney cancer	3.43e-05	0.000427	CcSEcCtD
Erlotinib—Renal impairment—Doxorubicin—kidney cancer	3.43e-05	0.000427	CcSEcCtD
Erlotinib—Dermatitis bullous—Doxorubicin—kidney cancer	3.41e-05	0.000425	CcSEcCtD
Erlotinib—Rash—Everolimus—kidney cancer	3.4e-05	0.000424	CcSEcCtD
Erlotinib—Dermatitis—Everolimus—kidney cancer	3.4e-05	0.000424	CcSEcCtD
Erlotinib—Headache—Vinblastine—kidney cancer	3.4e-05	0.000423	CcSEcCtD
Erlotinib—Headache—Everolimus—kidney cancer	3.38e-05	0.000421	CcSEcCtD
Erlotinib—Body temperature increased—Dactinomycin—kidney cancer	3.37e-05	0.00042	CcSEcCtD
Erlotinib—Abdominal pain—Dactinomycin—kidney cancer	3.37e-05	0.00042	CcSEcCtD
Erlotinib—Asthenia—Sorafenib—kidney cancer	3.36e-05	0.000419	CcSEcCtD
Erlotinib—Syncope—Paclitaxel—kidney cancer	3.33e-05	0.000415	CcSEcCtD
Erlotinib—Cerebrovascular accident—Doxorubicin—kidney cancer	3.33e-05	0.000415	CcSEcCtD
Erlotinib—Decreased appetite—Vincristine—kidney cancer	3.32e-05	0.000413	CcSEcCtD
Erlotinib—Pruritus—Sorafenib—kidney cancer	3.32e-05	0.000413	CcSEcCtD
Erlotinib—Erythema multiforme—Capecitabine—kidney cancer	3.31e-05	0.000412	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Gemcitabine—kidney cancer	3.3e-05	0.000411	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Vincristine—kidney cancer	3.29e-05	0.00041	CcSEcCtD
Erlotinib—Fatigue—Vincristine—kidney cancer	3.29e-05	0.00041	CcSEcCtD
Erlotinib—Insomnia—Gemcitabine—kidney cancer	3.27e-05	0.000408	CcSEcCtD
Erlotinib—Eye disorder—Capecitabine—kidney cancer	3.27e-05	0.000407	CcSEcCtD
Erlotinib—Loss of consciousness—Paclitaxel—kidney cancer	3.26e-05	0.000406	CcSEcCtD
Erlotinib—Constipation—Vincristine—kidney cancer	3.26e-05	0.000406	CcSEcCtD
Erlotinib—Pain—Vincristine—kidney cancer	3.26e-05	0.000406	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	3.26e-05	0.000406	CcSEcCtD
Erlotinib—Cough—Paclitaxel—kidney cancer	3.24e-05	0.000404	CcSEcCtD
Erlotinib—Asthenia—Sunitinib—kidney cancer	3.24e-05	0.000403	CcSEcCtD
Erlotinib—Dyspnoea—Gemcitabine—kidney cancer	3.23e-05	0.000402	CcSEcCtD
Erlotinib—Nausea—Vinblastine—kidney cancer	3.22e-05	0.000401	CcSEcCtD
Erlotinib—Nausea—Everolimus—kidney cancer	3.21e-05	0.0004	CcSEcCtD
Erlotinib—Diarrhoea—Sorafenib—kidney cancer	3.21e-05	0.000399	CcSEcCtD
Erlotinib—Pruritus—Sunitinib—kidney cancer	3.19e-05	0.000397	CcSEcCtD
Erlotinib—Chest pain—Paclitaxel—kidney cancer	3.16e-05	0.000394	CcSEcCtD
Erlotinib—Myalgia—Paclitaxel—kidney cancer	3.16e-05	0.000394	CcSEcCtD
Erlotinib—Arthralgia—Paclitaxel—kidney cancer	3.16e-05	0.000394	CcSEcCtD
Erlotinib—Mediastinal disorder—Capecitabine—kidney cancer	3.15e-05	0.000393	CcSEcCtD
Erlotinib—Anxiety—Paclitaxel—kidney cancer	3.15e-05	0.000392	CcSEcCtD
Erlotinib—Decreased appetite—Gemcitabine—kidney cancer	3.15e-05	0.000392	CcSEcCtD
Erlotinib—Chills—Capecitabine—kidney cancer	3.14e-05	0.000391	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	3.14e-05	0.000391	CcSEcCtD
Erlotinib—Arrhythmia—Capecitabine—kidney cancer	3.13e-05	0.000389	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Gemcitabine—kidney cancer	3.12e-05	0.000389	CcSEcCtD
Erlotinib—Fatigue—Gemcitabine—kidney cancer	3.12e-05	0.000389	CcSEcCtD
Erlotinib—Gastrointestinal pain—Vincristine—kidney cancer	3.12e-05	0.000389	CcSEcCtD
Erlotinib—Dizziness—Sorafenib—kidney cancer	3.1e-05	0.000386	CcSEcCtD
Erlotinib—Pain—Gemcitabine—kidney cancer	3.09e-05	0.000385	CcSEcCtD
Erlotinib—Constipation—Gemcitabine—kidney cancer	3.09e-05	0.000385	CcSEcCtD
Erlotinib—Alopecia—Capecitabine—kidney cancer	3.09e-05	0.000385	CcSEcCtD
Erlotinib—Diarrhoea—Sunitinib—kidney cancer	3.09e-05	0.000384	CcSEcCtD
Erlotinib—Mental disorder—Capecitabine—kidney cancer	3.07e-05	0.000382	CcSEcCtD
Erlotinib—Asthenia—Dactinomycin—kidney cancer	3.06e-05	0.000382	CcSEcCtD
Erlotinib—Malnutrition—Capecitabine—kidney cancer	3.05e-05	0.000379	CcSEcCtD
Erlotinib—Erythema—Capecitabine—kidney cancer	3.05e-05	0.000379	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—kidney cancer	3.03e-05	0.000378	CcSEcCtD
Erlotinib—Oedema—Paclitaxel—kidney cancer	3.03e-05	0.000377	CcSEcCtD
Erlotinib—Abdominal pain—Vincristine—kidney cancer	3.02e-05	0.000376	CcSEcCtD
Erlotinib—Body temperature increased—Vincristine—kidney cancer	3.02e-05	0.000376	CcSEcCtD
Erlotinib—Infection—Paclitaxel—kidney cancer	3.01e-05	0.000375	CcSEcCtD
Erlotinib—Flatulence—Capecitabine—kidney cancer	3e-05	0.000374	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—kidney cancer	2.99e-05	0.000372	CcSEcCtD
Erlotinib—Dizziness—Sunitinib—kidney cancer	2.98e-05	0.000371	CcSEcCtD
Erlotinib—Shock—Paclitaxel—kidney cancer	2.98e-05	0.000371	CcSEcCtD
Erlotinib—Vomiting—Sorafenib—kidney cancer	2.98e-05	0.000371	CcSEcCtD
Erlotinib—Nervous system disorder—Paclitaxel—kidney cancer	2.97e-05	0.00037	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—kidney cancer	2.97e-05	0.00037	CcSEcCtD
Erlotinib—Thrombocytopenia—Paclitaxel—kidney cancer	2.97e-05	0.00037	CcSEcCtD
Erlotinib—Rash—Sorafenib—kidney cancer	2.95e-05	0.000368	CcSEcCtD
Erlotinib—Dermatitis—Sorafenib—kidney cancer	2.95e-05	0.000368	CcSEcCtD
Erlotinib—Back pain—Capecitabine—kidney cancer	2.95e-05	0.000367	CcSEcCtD
Erlotinib—Skin disorder—Paclitaxel—kidney cancer	2.94e-05	0.000367	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	2.94e-05	0.000366	CcSEcCtD
Erlotinib—Headache—Sorafenib—kidney cancer	2.94e-05	0.000366	CcSEcCtD
Erlotinib—Diarrhoea—Dactinomycin—kidney cancer	2.92e-05	0.000364	CcSEcCtD
Erlotinib—Anorexia—Paclitaxel—kidney cancer	2.89e-05	0.00036	CcSEcCtD
Erlotinib—Gastritis—Doxorubicin—kidney cancer	2.89e-05	0.000359	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	2.88e-05	0.000358	CcSEcCtD
Erlotinib—Vomiting—Sunitinib—kidney cancer	2.87e-05	0.000357	CcSEcCtD
Erlotinib—Body temperature increased—Gemcitabine—kidney cancer	2.86e-05	0.000356	CcSEcCtD
Erlotinib—Rash—Sunitinib—kidney cancer	2.84e-05	0.000354	CcSEcCtD
Erlotinib—Dermatitis—Sunitinib—kidney cancer	2.84e-05	0.000354	CcSEcCtD
Erlotinib—Headache—Sunitinib—kidney cancer	2.82e-05	0.000352	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—kidney cancer	2.82e-05	0.000351	CcSEcCtD
Erlotinib—Nausea—Sorafenib—kidney cancer	2.78e-05	0.000347	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—kidney cancer	2.76e-05	0.000344	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	2.76e-05	0.000344	CcSEcCtD
Erlotinib—Insomnia—Paclitaxel—kidney cancer	2.74e-05	0.000341	CcSEcCtD
Erlotinib—Asthenia—Vincristine—kidney cancer	2.74e-05	0.000341	CcSEcCtD
Erlotinib—Syncope—Capecitabine—kidney cancer	2.73e-05	0.00034	CcSEcCtD
Erlotinib—Vomiting—Dactinomycin—kidney cancer	2.71e-05	0.000338	CcSEcCtD
Erlotinib—Dyspnoea—Paclitaxel—kidney cancer	2.7e-05	0.000336	CcSEcCtD
Erlotinib—Rash—Dactinomycin—kidney cancer	2.69e-05	0.000335	CcSEcCtD
Erlotinib—Nausea—Sunitinib—kidney cancer	2.68e-05	0.000334	CcSEcCtD
Erlotinib—Loss of consciousness—Capecitabine—kidney cancer	2.68e-05	0.000334	CcSEcCtD
Erlotinib—Dyspepsia—Paclitaxel—kidney cancer	2.67e-05	0.000332	CcSEcCtD
Erlotinib—Cough—Capecitabine—kidney cancer	2.66e-05	0.000331	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—kidney cancer	2.64e-05	0.000328	CcSEcCtD
Erlotinib—Decreased appetite—Paclitaxel—kidney cancer	2.63e-05	0.000328	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Paclitaxel—kidney cancer	2.62e-05	0.000326	CcSEcCtD
Erlotinib—Fatigue—Paclitaxel—kidney cancer	2.61e-05	0.000325	CcSEcCtD
Erlotinib—Diarrhoea—Vincristine—kidney cancer	2.61e-05	0.000325	CcSEcCtD
Erlotinib—Asthenia—Gemcitabine—kidney cancer	2.6e-05	0.000323	CcSEcCtD
Erlotinib—Arthralgia—Capecitabine—kidney cancer	2.59e-05	0.000323	CcSEcCtD
Erlotinib—Chest pain—Capecitabine—kidney cancer	2.59e-05	0.000323	CcSEcCtD
Erlotinib—Myalgia—Capecitabine—kidney cancer	2.59e-05	0.000323	CcSEcCtD
Erlotinib—Pain—Paclitaxel—kidney cancer	2.59e-05	0.000323	CcSEcCtD
Erlotinib—Constipation—Paclitaxel—kidney cancer	2.59e-05	0.000323	CcSEcCtD
Erlotinib—Anxiety—Capecitabine—kidney cancer	2.58e-05	0.000322	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	2.58e-05	0.000321	CcSEcCtD
Erlotinib—Pruritus—Gemcitabine—kidney cancer	2.56e-05	0.000319	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—kidney cancer	2.55e-05	0.000318	CcSEcCtD
Erlotinib—Nausea—Dactinomycin—kidney cancer	2.54e-05	0.000316	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—kidney cancer	2.53e-05	0.000315	CcSEcCtD
Erlotinib—Dizziness—Vincristine—kidney cancer	2.52e-05	0.000314	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—kidney cancer	2.51e-05	0.000313	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—kidney cancer	2.51e-05	0.000313	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	2.49e-05	0.00031	CcSEcCtD
Erlotinib—Oedema—Capecitabine—kidney cancer	2.49e-05	0.00031	CcSEcCtD
Erlotinib—Gastrointestinal pain—Paclitaxel—kidney cancer	2.48e-05	0.000309	CcSEcCtD
Erlotinib—Diarrhoea—Gemcitabine—kidney cancer	2.48e-05	0.000308	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—kidney cancer	2.47e-05	0.000308	CcSEcCtD
Erlotinib—Infection—Capecitabine—kidney cancer	2.47e-05	0.000308	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—kidney cancer	2.46e-05	0.000307	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—kidney cancer	2.45e-05	0.000305	CcSEcCtD
Erlotinib—Shock—Capecitabine—kidney cancer	2.45e-05	0.000305	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—kidney cancer	2.44e-05	0.000304	CcSEcCtD
Erlotinib—Nervous system disorder—Capecitabine—kidney cancer	2.44e-05	0.000304	CcSEcCtD
Erlotinib—Thrombocytopenia—Capecitabine—kidney cancer	2.43e-05	0.000303	CcSEcCtD
Erlotinib—Vomiting—Vincristine—kidney cancer	2.43e-05	0.000302	CcSEcCtD
Erlotinib—Skin disorder—Capecitabine—kidney cancer	2.41e-05	0.000301	CcSEcCtD
Erlotinib—Rash—Vincristine—kidney cancer	2.4e-05	0.0003	CcSEcCtD
Erlotinib—Dermatitis—Vincristine—kidney cancer	2.4e-05	0.000299	CcSEcCtD
Erlotinib—Abdominal pain—Paclitaxel—kidney cancer	2.39e-05	0.000298	CcSEcCtD
Erlotinib—Body temperature increased—Paclitaxel—kidney cancer	2.39e-05	0.000298	CcSEcCtD
Erlotinib—Headache—Vincristine—kidney cancer	2.39e-05	0.000298	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—kidney cancer	2.38e-05	0.000296	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—kidney cancer	2.37e-05	0.000295	CcSEcCtD
Erlotinib—Anorexia—Capecitabine—kidney cancer	2.37e-05	0.000295	CcSEcCtD
Erlotinib—Vomiting—Gemcitabine—kidney cancer	2.3e-05	0.000287	CcSEcCtD
Erlotinib—Rash—Gemcitabine—kidney cancer	2.28e-05	0.000284	CcSEcCtD
Erlotinib—Dermatitis—Gemcitabine—kidney cancer	2.28e-05	0.000284	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—kidney cancer	2.27e-05	0.000282	CcSEcCtD
Erlotinib—Headache—Gemcitabine—kidney cancer	2.27e-05	0.000282	CcSEcCtD
Erlotinib—Nausea—Vincristine—kidney cancer	2.27e-05	0.000282	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Capecitabine—kidney cancer	2.26e-05	0.000282	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—kidney cancer	2.26e-05	0.000281	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—kidney cancer	2.26e-05	0.000281	CcSEcCtD
Erlotinib—Insomnia—Capecitabine—kidney cancer	2.25e-05	0.00028	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—kidney cancer	2.23e-05	0.000278	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—kidney cancer	2.22e-05	0.000276	CcSEcCtD
Erlotinib—Dyspnoea—Capecitabine—kidney cancer	2.22e-05	0.000276	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—kidney cancer	2.21e-05	0.000275	CcSEcCtD
Erlotinib—Dyspepsia—Capecitabine—kidney cancer	2.19e-05	0.000273	CcSEcCtD
Erlotinib—Asthenia—Paclitaxel—kidney cancer	2.17e-05	0.000271	CcSEcCtD
Erlotinib—Decreased appetite—Capecitabine—kidney cancer	2.16e-05	0.000269	CcSEcCtD
Erlotinib—Nausea—Gemcitabine—kidney cancer	2.15e-05	0.000268	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Capecitabine—kidney cancer	2.15e-05	0.000267	CcSEcCtD
Erlotinib—Fatigue—Capecitabine—kidney cancer	2.14e-05	0.000267	CcSEcCtD
Erlotinib—Pruritus—Paclitaxel—kidney cancer	2.14e-05	0.000267	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—kidney cancer	2.13e-05	0.000266	CcSEcCtD
Erlotinib—Pain—Capecitabine—kidney cancer	2.13e-05	0.000265	CcSEcCtD
Erlotinib—Constipation—Capecitabine—kidney cancer	2.13e-05	0.000265	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—kidney cancer	2.11e-05	0.000263	CcSEcCtD
Erlotinib—Diarrhoea—Paclitaxel—kidney cancer	2.07e-05	0.000258	CcSEcCtD
Erlotinib—Gastrointestinal pain—Capecitabine—kidney cancer	2.03e-05	0.000253	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—kidney cancer	2.03e-05	0.000253	CcSEcCtD
Erlotinib—Chills—Doxorubicin—kidney cancer	2.02e-05	0.000252	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—kidney cancer	2.01e-05	0.000251	CcSEcCtD
Erlotinib—Dizziness—Paclitaxel—kidney cancer	2e-05	0.00025	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—kidney cancer	1.99e-05	0.000248	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—kidney cancer	1.98e-05	0.000246	CcSEcCtD
Erlotinib—Body temperature increased—Capecitabine—kidney cancer	1.97e-05	0.000245	CcSEcCtD
Erlotinib—Abdominal pain—Capecitabine—kidney cancer	1.97e-05	0.000245	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—kidney cancer	1.96e-05	0.000245	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—kidney cancer	1.96e-05	0.000245	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—kidney cancer	1.93e-05	0.000241	CcSEcCtD
Erlotinib—Vomiting—Paclitaxel—kidney cancer	1.93e-05	0.00024	CcSEcCtD
Erlotinib—Rash—Paclitaxel—kidney cancer	1.91e-05	0.000238	CcSEcCtD
Erlotinib—Dermatitis—Paclitaxel—kidney cancer	1.91e-05	0.000238	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—kidney cancer	1.9e-05	0.000237	CcSEcCtD
Erlotinib—Headache—Paclitaxel—kidney cancer	1.9e-05	0.000236	CcSEcCtD
Erlotinib—Nausea—Paclitaxel—kidney cancer	1.8e-05	0.000224	CcSEcCtD
Erlotinib—Asthenia—Capecitabine—kidney cancer	1.78e-05	0.000222	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—kidney cancer	1.76e-05	0.000219	CcSEcCtD
Erlotinib—Pruritus—Capecitabine—kidney cancer	1.76e-05	0.000219	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—kidney cancer	1.73e-05	0.000215	CcSEcCtD
Erlotinib—Cough—Doxorubicin—kidney cancer	1.71e-05	0.000213	CcSEcCtD
Erlotinib—Diarrhoea—Capecitabine—kidney cancer	1.7e-05	0.000212	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—kidney cancer	1.67e-05	0.000208	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—kidney cancer	1.67e-05	0.000208	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—kidney cancer	1.67e-05	0.000208	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—kidney cancer	1.67e-05	0.000208	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.66e-05	0.000207	CcSEcCtD
Erlotinib—Dizziness—Capecitabine—kidney cancer	1.64e-05	0.000205	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—kidney cancer	1.6e-05	0.0002	CcSEcCtD
Erlotinib—Infection—Doxorubicin—kidney cancer	1.59e-05	0.000198	CcSEcCtD
Erlotinib—Vomiting—Capecitabine—kidney cancer	1.58e-05	0.000197	CcSEcCtD
Erlotinib—Shock—Doxorubicin—kidney cancer	1.58e-05	0.000196	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—kidney cancer	1.57e-05	0.000196	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—kidney cancer	1.57e-05	0.000195	CcSEcCtD
Erlotinib—Rash—Capecitabine—kidney cancer	1.57e-05	0.000195	CcSEcCtD
Erlotinib—Dermatitis—Capecitabine—kidney cancer	1.57e-05	0.000195	CcSEcCtD
Erlotinib—Headache—Capecitabine—kidney cancer	1.56e-05	0.000194	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—kidney cancer	1.56e-05	0.000194	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—kidney cancer	1.53e-05	0.00019	CcSEcCtD
Erlotinib—Nausea—Capecitabine—kidney cancer	1.48e-05	0.000184	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.46e-05	0.000182	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—kidney cancer	1.45e-05	0.000181	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—kidney cancer	1.43e-05	0.000178	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—kidney cancer	1.41e-05	0.000176	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—kidney cancer	1.39e-05	0.000174	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.38e-05	0.000172	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—kidney cancer	1.38e-05	0.000172	CcSEcCtD
Erlotinib—Pain—Doxorubicin—kidney cancer	1.37e-05	0.000171	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—kidney cancer	1.37e-05	0.000171	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—kidney cancer	1.31e-05	0.000163	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—kidney cancer	1.27e-05	0.000158	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—kidney cancer	1.27e-05	0.000158	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—kidney cancer	1.15e-05	0.000143	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—kidney cancer	1.13e-05	0.000141	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—kidney cancer	1.1e-05	0.000137	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—kidney cancer	1.06e-05	0.000132	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—kidney cancer	1.02e-05	0.000127	CcSEcCtD
Erlotinib—Rash—Doxorubicin—kidney cancer	1.01e-05	0.000126	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—kidney cancer	1.01e-05	0.000126	CcSEcCtD
Erlotinib—Headache—Doxorubicin—kidney cancer	1e-05	0.000125	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—kidney cancer	9.52e-06	0.000119	CcSEcCtD
Erlotinib—CYP2C8—Metabolism—SCARB1—kidney cancer	1.73e-06	3.47e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD4—kidney cancer	1.72e-06	3.47e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.72e-06	3.46e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SCARB1—kidney cancer	1.72e-06	3.45e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1R—kidney cancer	1.72e-06	3.45e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC5A5—kidney cancer	1.71e-06	3.44e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS1—kidney cancer	1.71e-06	3.44e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—kidney cancer	1.7e-06	3.43e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.7e-06	3.43e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—kidney cancer	1.7e-06	3.42e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS1—kidney cancer	1.7e-06	3.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KRAS—kidney cancer	1.68e-06	3.38e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PSMD7—kidney cancer	1.67e-06	3.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—BRAF—kidney cancer	1.67e-06	3.36e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CDKN1B—kidney cancer	1.67e-06	3.36e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PSMD7—kidney cancer	1.67e-06	3.35e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.66e-06	3.35e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—RAF1—kidney cancer	1.66e-06	3.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—RAF1—kidney cancer	1.65e-06	3.33e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC2A1—kidney cancer	1.65e-06	3.33e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ITPR2—kidney cancer	1.64e-06	3.3e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2—kidney cancer	1.63e-06	3.28e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CDKN1B—kidney cancer	1.62e-06	3.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KRAS—kidney cancer	1.61e-06	3.25e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MAPK3—kidney cancer	1.61e-06	3.24e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.6e-06	3.23e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.6e-06	3.22e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PGK1—kidney cancer	1.6e-06	3.21e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.6e-06	3.21e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCND1—kidney cancer	1.59e-06	3.2e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTT1—kidney cancer	1.59e-06	3.2e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ACHE—kidney cancer	1.59e-06	3.2e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—BCHE—kidney cancer	1.59e-06	3.2e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—JUN—kidney cancer	1.59e-06	3.2e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2—kidney cancer	1.58e-06	3.19e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—BCHE—kidney cancer	1.58e-06	3.18e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CTNNB1—kidney cancer	1.58e-06	3.17e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC5A5—kidney cancer	1.57e-06	3.16e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—LDHB—kidney cancer	1.57e-06	3.15e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—kidney cancer	1.56e-06	3.15e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC5A5—kidney cancer	1.56e-06	3.14e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—POMC—kidney cancer	1.56e-06	3.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PIK3CA—kidney cancer	1.54e-06	3.11e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—JUN—kidney cancer	1.54e-06	3.1e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTEN—kidney cancer	1.54e-06	3.09e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MAPK1—kidney cancer	1.53e-06	3.08e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTNNB1—kidney cancer	1.53e-06	3.08e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC2A1—kidney cancer	1.51e-06	3.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—RAF1—kidney cancer	1.51e-06	3.04e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC2A1—kidney cancer	1.51e-06	3.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—RELA—kidney cancer	1.5e-06	3.03e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SCARB1—kidney cancer	1.5e-06	3.03e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTT1—kidney cancer	1.5e-06	3.01e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ACHE—kidney cancer	1.5e-06	3.01e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CRABP1—kidney cancer	1.5e-06	3.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—kidney cancer	1.49e-06	3.01e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—kidney cancer	1.49e-06	3e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS1—kidney cancer	1.49e-06	3e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—kidney cancer	1.49e-06	3e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—kidney cancer	1.48e-06	2.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PIK3CA—kidney cancer	1.48e-06	2.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MTOR—kidney cancer	1.47e-06	2.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD4—kidney cancer	1.47e-06	2.96e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.47e-06	2.96e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.46e-06	2.94e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PSMD7—kidney cancer	1.46e-06	2.94e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTP1—kidney cancer	1.46e-06	2.94e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—POMC—kidney cancer	1.45e-06	2.93e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—kidney cancer	1.45e-06	2.91e-05	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	1.44e-06	2.89e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SCARB1—kidney cancer	1.42e-06	2.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HIF1A—kidney cancer	1.41e-06	2.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TSC2—kidney cancer	1.41e-06	2.84e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS1—kidney cancer	1.4e-06	2.82e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.4e-06	2.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—RAF1—kidney cancer	1.39e-06	2.81e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ITPR2—kidney cancer	1.39e-06	2.8e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—kidney cancer	1.39e-06	2.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1B—kidney cancer	1.38e-06	2.79e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—BCHE—kidney cancer	1.38e-06	2.78e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ABCB1—kidney cancer	1.38e-06	2.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—kidney cancer	1.38e-06	2.78e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTP1—kidney cancer	1.38e-06	2.77e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PSMD7—kidney cancer	1.38e-06	2.77e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC5A5—kidney cancer	1.37e-06	2.75e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTOR—kidney cancer	1.36e-06	2.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD4—kidney cancer	1.36e-06	2.74e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CA9—kidney cancer	1.36e-06	2.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—kidney cancer	1.35e-06	2.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KDR—kidney cancer	1.35e-06	2.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—kidney cancer	1.35e-06	2.72e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTM1—kidney cancer	1.34e-06	2.7e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—kidney cancer	1.33e-06	2.67e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—POMC—kidney cancer	1.32e-06	2.66e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC2A1—kidney cancer	1.32e-06	2.66e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—JUN—kidney cancer	1.32e-06	2.65e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK3—kidney cancer	1.31e-06	2.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—kidney cancer	1.31e-06	2.63e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ABCB1—kidney cancer	1.3e-06	2.63e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—BCHE—kidney cancer	1.3e-06	2.62e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.29e-06	2.59e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—kidney cancer	1.29e-06	2.59e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.28e-06	2.58e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.28e-06	2.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1B—kidney cancer	1.28e-06	2.57e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—kidney cancer	1.28e-06	2.57e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.27e-06	2.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—kidney cancer	1.27e-06	2.57e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK3—kidney cancer	1.27e-06	2.56e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP1A1—kidney cancer	1.27e-06	2.56e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTT1—kidney cancer	1.27e-06	2.55e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ACHE—kidney cancer	1.27e-06	2.55e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTM1—kidney cancer	1.27e-06	2.55e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—kidney cancer	1.26e-06	2.55e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTP1—kidney cancer	1.26e-06	2.54e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	1.26e-06	2.53e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTP1—kidney cancer	1.26e-06	2.53e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK1—kidney cancer	1.25e-06	2.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APC—kidney cancer	1.24e-06	2.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIT—kidney cancer	1.24e-06	2.5e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.24e-06	2.5e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—kidney cancer	1.24e-06	2.5e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK1—kidney cancer	1.21e-06	2.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—kidney cancer	1.21e-06	2.43e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SCARB1—kidney cancer	1.2e-06	2.42e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK3—kidney cancer	1.2e-06	2.41e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCB1—kidney cancer	1.2e-06	2.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK3—kidney cancer	1.19e-06	2.4e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCB1—kidney cancer	1.19e-06	2.39e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS1—kidney cancer	1.19e-06	2.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—POMC—kidney cancer	1.18e-06	2.38e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—kidney cancer	1.18e-06	2.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—kidney cancer	1.18e-06	2.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—kidney cancer	1.17e-06	2.35e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PSMD7—kidney cancer	1.16e-06	2.35e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—kidney cancer	1.16e-06	2.34e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—kidney cancer	1.16e-06	2.33e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—kidney cancer	1.15e-06	2.32e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CRABP1—kidney cancer	1.15e-06	2.32e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—kidney cancer	1.14e-06	2.31e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—MAPK1—kidney cancer	1.14e-06	2.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—MAPK1—kidney cancer	1.13e-06	2.28e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—BCHE—kidney cancer	1.1e-06	2.22e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—kidney cancer	1.1e-06	2.22e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP1A1—kidney cancer	1.1e-06	2.22e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP1A1—kidney cancer	1.09e-06	2.2e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC5A5—kidney cancer	1.09e-06	2.2e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK3—kidney cancer	1.09e-06	2.19e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—kidney cancer	1.08e-06	2.18e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—kidney cancer	1.08e-06	2.18e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—kidney cancer	1.07e-06	2.16e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ITPR2—kidney cancer	1.07e-06	2.16e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—kidney cancer	1.07e-06	2.16e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—kidney cancer	1.05e-06	2.12e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A1—kidney cancer	1.05e-06	2.12e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—kidney cancer	1.05e-06	2.12e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—kidney cancer	1.05e-06	2.11e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—kidney cancer	1.04e-06	2.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK1—kidney cancer	1.04e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.02e-06	2.06e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—kidney cancer	1.01e-06	2.04e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—kidney cancer	1.01e-06	2.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK3—kidney cancer	1.01e-06	2.02e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—kidney cancer	9.87e-07	1.99e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	9.86e-07	1.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—kidney cancer	9.84e-07	1.98e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—kidney cancer	9.82e-07	1.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—kidney cancer	9.78e-07	1.97e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—kidney cancer	9.78e-07	1.97e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ACHE—kidney cancer	9.78e-07	1.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—kidney cancer	9.78e-07	1.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RAF1—kidney cancer	9.76e-07	1.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RELA—kidney cancer	9.72e-07	1.96e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—kidney cancer	9.66e-07	1.94e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1A1—kidney cancer	9.59e-07	1.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MAPK1—kidney cancer	9.56e-07	1.93e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—kidney cancer	9.55e-07	1.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MTOR—kidney cancer	9.53e-07	1.92e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—kidney cancer	9.53e-07	1.92e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—POMC—kidney cancer	9.47e-07	1.91e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SCARB1—kidney cancer	9.26e-07	1.86e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—kidney cancer	9.2e-07	1.85e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS1—kidney cancer	9.17e-07	1.85e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	9.04e-07	1.82e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1A1—kidney cancer	9.04e-07	1.82e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—kidney cancer	9.03e-07	1.82e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.99e-07	1.81e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PSMD7—kidney cancer	8.99e-07	1.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—kidney cancer	8.99e-07	1.81e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—POMC—kidney cancer	8.95e-07	1.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1B—kidney cancer	8.95e-07	1.8e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.91e-07	1.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—kidney cancer	8.79e-07	1.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—kidney cancer	8.76e-07	1.76e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—kidney cancer	8.53e-07	1.72e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—BCHE—kidney cancer	8.52e-07	1.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JUN—kidney cancer	8.52e-07	1.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—kidney cancer	8.45e-07	1.7e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A5—kidney cancer	8.42e-07	1.69e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—kidney cancer	8.32e-07	1.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—kidney cancer	8.3e-07	1.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—kidney cancer	8.24e-07	1.66e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—POMC—kidney cancer	8.21e-07	1.65e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—POMC—kidney cancer	8.16e-07	1.64e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A1—kidney cancer	8.13e-07	1.64e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—kidney cancer	8.07e-07	1.63e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1A1—kidney cancer	7.65e-07	1.54e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—kidney cancer	7.65e-07	1.54e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—kidney cancer	7.56e-07	1.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—kidney cancer	7.44e-07	1.5e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—POMC—kidney cancer	7.15e-07	1.44e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—kidney cancer	7.14e-07	1.44e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—kidney cancer	7.13e-07	1.44e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK3—kidney cancer	7.04e-07	1.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—kidney cancer	6.85e-07	1.38e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—kidney cancer	6.78e-07	1.37e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—POMC—kidney cancer	6.74e-07	1.36e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK1—kidney cancer	6.7e-07	1.35e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—kidney cancer	6.59e-07	1.33e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—kidney cancer	6.54e-07	1.32e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—kidney cancer	6.51e-07	1.31e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—kidney cancer	6.49e-07	1.31e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—kidney cancer	6.42e-07	1.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—kidney cancer	6.33e-07	1.27e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.29e-07	1.27e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—kidney cancer	6.23e-07	1.25e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—kidney cancer	6.23e-07	1.25e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1A1—kidney cancer	5.91e-07	1.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—kidney cancer	5.81e-07	1.17e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—kidney cancer	5.71e-07	1.15e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—POMC—kidney cancer	5.71e-07	1.15e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—kidney cancer	5.7e-07	1.15e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—kidney cancer	5.68e-07	1.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—kidney cancer	5.62e-07	1.13e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—kidney cancer	5.37e-07	1.08e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—kidney cancer	4.97e-07	1e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—kidney cancer	4.69e-07	9.43e-06	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—kidney cancer	4.65e-07	9.36e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—kidney cancer	4.55e-07	9.16e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—POMC—kidney cancer	4.4e-07	8.87e-06	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—kidney cancer	4.39e-07	8.84e-06	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—kidney cancer	4.03e-07	8.11e-06	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—kidney cancer	4e-07	8.06e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—kidney cancer	3.97e-07	7.99e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—kidney cancer	3.51e-07	7.07e-06	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—kidney cancer	3.51e-07	7.06e-06	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—kidney cancer	3.31e-07	6.66e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—kidney cancer	3.06e-07	6.17e-06	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.8e-07	5.64e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—kidney cancer	2.16e-07	4.35e-06	CbGpPWpGaD
